Comparative Pharmacology
Head-to-head clinical analysis: CHIBROXIN versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIBROXIN versus GEMIFLOXACIN MESYLATE.
CHIBROXIN vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chibroxin (norfloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
1-2 drops of 0.3% ophthalmic solution into affected eye(s) every 2 hours while awake for the first 2 days, then every 4 hours for 5-7 days.
320 mg orally once daily for 7-14 days
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function. Prolonged to 12-24 hours in moderate renal impairment (CrCl 30-50 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Renal: 98% as unchanged drug; hepatic: 2% as minor metabolites. Biliary/fecal excretion negligible.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic